{
    "title": "106_hr1039",
    "content": "SECTION 1. CREDIT FOR CLINICAL TESTING RESEARCH EXPENSES ATTRIBUTABLE TO CERTAIN QUALIFIED ACADEMIC INSTITUTIONS INCLUDING TEACHING HOSPITALS. An amendment is made to the Internal Revenue Code of 1986 to include a credit for medical innovation expenses. The medical innovation credit under section 38 is 20% of qualified medical innovation expenses exceeding the medical innovation base period amount. Qualified expenses are those paid to a qualified academic institution for clinical testing research activities. The term 'expenses' refers to amounts paid to a qualified academic institution for clinical testing research activities before product approval. The term 'expenses' refers to amounts paid to a qualified academic institution for clinical testing research activities before product approval, which occurs before the date of application approval, product license issuance, or product classification for a device. The term 'product' refers to any drug, biologic, or medical device issued under specific sections of the Public Health Service Act or the Federal Food, Drug, and Cosmetic Act. A 'qualified academic institution' is defined as certain types of educational institutions. The term 'product' includes drugs, biologics, or medical devices. A 'qualified academic institution' is defined as an educational institution or a teaching hospital. A teaching hospital affiliated with a publicly supported organization described in section 501(c)(3) is considered a qualified academic institution. Charitable research hospital designated as a cancer center by the National Cancer Institute. The term 'qualified medical innovation expenses' excludes amounts funded by grants or contracts from another person or governmental entity. The 'medical innovation base period amount' is defined for this section. For tax purposes, the term 'medical innovation base period amount' refers to the average annual qualified medical innovation expenses paid by the taxpayer in the three years before the first taxable year after December 31, 1998. No credit is allowed for clinical testing funded by foreign sources. The tax credit for medical innovation is based on the average annual qualified medical innovation expenses in the three years before the first taxable year after December 31, 1998. No credit is allowed for clinical testing conducted outside the United States, and certain rules from section 41 apply. Taxpayers must elect to apply this section for each taxable year. The tax credit for medical innovation is based on qualified medical innovation expenses. Taxpayers must elect to apply this section for each taxable year, and certain rules from section 41 apply. The tax credit for medical innovation allows for the exclusion of innovation expenses from the calculation of the credit under sections 41 or 45C. This section does not apply to expenses incurred after a specified date. The tax code is amended to include a medical innovation expenses credit under section 41A(a), with a transition rule preventing the carryback of this credit before enactment. The tax code is amended to include a medical innovation expenses credit under section 41A(a), with a transition rule preventing the carryback of this credit before enactment. Additionally, a denial of double benefit is included in section 280C to address the credit for increasing medical innovation expenses. The tax code is amended to include a credit for increasing medical innovation expenses under section 41A(a), with a denial of double benefit in section 280C. No deduction is allowed for the portion of qualified medical innovation expenses equal to the credit determined for the taxable year. The tax code amendment includes a credit for medical innovation expenses under section 41A(a), with rules similar to subsection (c) applying. A deduction is not allowed for the portion of qualified medical innovation expenses equal to the credit determined for the taxable year. The tax code amendment introduces a medical innovation expenses credit under section 41A(a), with rules similar to subsection (c) applying. The table of sections for subpart D of part IV of subchapter A of chapter 1 of the Code is amended to include this new credit. The tax code amendment introduces a medical innovation expenses credit under section 41A, effective for taxable years starting after December 31, 1998."
}